- |||||||||| GSK3965193 / GSK
Journal: TRPV4 modulation participates in paraoxon-induced brain injury via NMDA and NLRP3 regulation. (Pubmed Central) - May 7, 2024
In vivo, we examined the survival rate, behavioral seizures, histopathological alterations, NMDA receptor phosphorylation, as well as the expression of the NLRP3-ASC-caspase-1 complex and downstream inflammatory factors in the POX poisoning model following intervention with the TRPV4 antagonist GSK2193874...Moreover, the TRPV4 antagonist corrected the NMDA-induced increase in inward current and cell death rate, decrease in cell viability, and Ca2+ accumulation. TRPV4 participates in the mechanisms of brain injury induced by POX exposure through NMDA-mediated excitotoxicity and NLRP3-mediated inflammatory response.
- |||||||||| Nulojix (belatacept) / BMS
Tailored De Novo Belatacept Regimens: Long-Term Clinical Outcomes in Adolescent Kidney Transplantation (107-AB, Level 1) - May 6, 2024 - Abstract #ATC2024ATC_2903;
All 7 patients received intra-operative alemtuzumab and methylprednisolone induction and belatacept maintenance therapy...Of these, two converted from sirolimus to steroids and mycophenolate mofetil (MMF)...One patient was maintained on belatacept and belimumab to prevent lupus recurrence... Tailored belatacept-based regimens demonstrate favorable long-term outcomes in a patient population who are susceptible to allograft dysfunction and medication nonadherence.
- |||||||||| Arexvy (respiratory syncytial virus vaccine, adjuvanted) / GSK, Abrysvo (PF-06928316) / Pfizer
Heterogenous Respiratory Syncytial Virus Vaccine Immunogenicity in Solid Organ Transplant Recipients (Ballroom AB, Level 3) - May 6, 2024 - Abstract #ATC2024ATC_2033;
CF can significantly alleviate acute rejection of heart transplantation in mice, by inhibiting T cells proliferation, reducing the proportions of Th1 cells and decreasing proinflammatory cytokines level. Therefore, we sought to evaluate the humoral vaccine response to clinically available RSV vaccines in this at-risk population.* In a national prospective cohort, we measured Anti-RSV Pre-Fusion F IgG antibody (PreF Ab) using the Meso Scale Diagnostics respiratory panel 1 in SOTRs who received the RSVPreF3 (GSK, AREXVY
- |||||||||| Livtencity (maribavir) / Takeda, GSK
Results from the French Compassionate Program of Maribavir Use for Refractory CMV Infection/Disease (117, Level 1) - May 6, 2024 - Abstract #ATC2024ATC_1861;
P3
The population analyzed differed from the SOLSTICE population in that it had a higher proportion of SOT recipients, with CMV disease, more severe biological criteria and with identified antiviral resistance. Despite the more severe CUP patient profiles, the results showed coherent efficacy and safety findings with the pivotal study.
- |||||||||| Prolia (denosumab) / Amgen
Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_1652;
Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Livtencity (maribavir) / Takeda, GSK
Real World Experience of Maribavir Use for Cytomegalovirus Infection after Kidney Transplantation (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_1412;
Most common adverse reactions included taste alteration, GI upset, and fatigue. There was no indication for empiric tacrolimus dose adjustments upon initiating maribavir, but levels should be closely monitored for possible dose reduction in some patients.
- |||||||||| Comparative Effectiveness of Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_904;
SOTRs who received outpatient mAb or antiviral treatment for mild-to-moderate COVID-19 had comparable clinical outcomes, as measured by odds of hospitalization. Clinicians may use any of these treatment options according to the individual patient's circumstances and without concern for differential therapeutic efficacy.
- |||||||||| Livtencity (maribavir) / Takeda, GSK
P1 data, PK/PD data, Journal: Effect of Food, Crushing of Tablets, and Antacid Coadministration on Maribavir Pharmacokinetics in Healthy Adult Participants: Results From 2 Phase 1, Open-Label, Randomized, Crossover Studies. (Pubmed Central) - May 6, 2024
Maribavir median time to Cmax value in plasma under fed conditions was delayed versus fasting conditions, but there was no statistical difference for crushed versus whole tablet or with versus without antacid. As the antiviral efficacy of maribavir is driven by AUC but not Cmax, findings suggest that maribavir can be administered with food or antacids or as a crushed tablet.
- |||||||||| Leukeran (chlorambucil) / GSK
Review, Journal: Pharmacology of drugs used in autoimmune dermatopathies in cats and dogs: A narrative review. (Pubmed Central) - May 6, 2024
This review paper will focus on the mechanism of action, pharmacokinetics and pharmacodynamics, clinical uses and adverse effects of immunosuppressive drugs used to treat autoimmune dermatoses in cats and dogs. These include glucocorticoids, ciclosporin A, azathioprine, chlorambucil, mycophenolate mofetil, oclacitinib and Bruton's tyrosine kinase inhibitors.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective. (Pubmed Central) - May 6, 2024
Of particular note, clinical and preclinical studies suggest that commonly prescribed osteoporosis drugs like bisphosphonates, intermittent parathyroid hormone, anti-sclerostin antibody, selective estrogen receptor modulators and anti-receptor activator of nuclear factor-kappa B ligand inhibitor denosumab may also relieve back pain. Here, we cite clinical and preclinical studies and include unpublished data to support the argument that a subset of these therapeutics for osteoporosis may alleviate low back pain by also targeting the IVD.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Use of botox for sialorrhea and dysphagia in the neonatal population. (Pubmed Central) - May 5, 2024
BoNT injection is a safe, non-invasive alterative for management of sialorrhea in neonates. Further extensive study needs to be performed to identify the optimal dose per gland in this population.
- |||||||||| Sovaldi (sofosbuvir) / Gilead
Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase III, Journal: Vaccine-derived yellow fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with sofosbuvir. (Pubmed Central) - May 5, 2024
To avoid a potentially severe course of the disease, sofosbuvir was used as antiviral treatment followed by the resolution of symptoms and serological response. As travelers with chronic diseases and immunosuppression will increasingly engage in long distance travel, this case demonstrates the importance of assessing patient history prior to the administration of live vaccines and points towards a possible therapeutic approach in those suffering from vaccine-associated YF.
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Ocrevus (ocrelizumab) / Roche, Biogen
Journal, Real-world evidence, Real-world: Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study. (Pubmed Central) - May 5, 2024
The treatment with OCR and OFA resulted in comparable control of disease activity with good safety profile. Our results need further validation in larger multicentre studies with long-term follow-up.
- |||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV. (Pubmed Central) - May 5, 2024
Despite placental transfer, no congenital malformations were noted. Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Paraganglioma or Benign Ectopic Thyroid Tissue? (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2938;
Even a very thorough workup can mistake the identity of a mysterious mass; only the tissue itself can make the diagnosis.References: 1. Cooper, David S., and Paul W. Ladenson.
- |||||||||| Prolia (denosumab) / Amgen
Using High-Resolution Peripheral Quantitative Computed Tomography to Assess Bone Microarchitecture and Guide Osteoporosis Treatment (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2695;
Therefore, denosumab, which has been shown to decrease cortical porosity, was chosen...Currently, the lack of sufficient validated normative data for HR-pQCT limits its widespread use in the diagnosis of osteoporosis and fracture prediction. However, given that HR-pQCT can characterize the properties of trabecular and cortical bone, it may have a role in helping guide osteoporosis treatment, especially in challenging and atypical cases.
- |||||||||| Prolia (denosumab) / Amgen
The Silent Thief: Neurofibromatosis Type 1 (NF1) Leading to Severe Osteoporosis and Recurrent Bone Fractures (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2690;
Bisphosphonates and denosumab were not prescribed due to the lack of guidelines on NF1 population...However, a recent clinical trial involving 141 NF1 adults identified that weight-bearing exercise, optimizing calcium and 25-hydroxyvitamin D intake and increased sun exposure can minimize BMD loss. However, guidelines for the management of bone abnormalities in NF1, including earlier screening and prophylactic therapy with vitamin D, are needed.
- |||||||||| Prolia (denosumab) / Amgen
Thrombotic Events in Primary Hyperparathyroidism: Association or Coincidence? (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2676;
However, guidelines for the management of bone abnormalities in NF1, including earlier screening and prophylactic therapy with vitamin D, are needed. Following treatment with intravenous fluids, Calcitonin, and Denosumab, her calcium level improved to 10.1 mg/dL...The patient
- |||||||||| De Novo Metastatic Breast Cancer after Bilateral Mastectomy in a Transgender Man Harbouring a Germline BRCA2 mutation (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1766;
A multigenerational family history of breast cancer prompted genetic testing, identifying a BRCA2 germline mutation.Past medical history included brain stem glioma (diagnosed aged 13 years) with multiple intracranial surgeries, ventriculoperitoneal shunt, mild acquired brain injury, anxiety, and post-traumatic stress disorder.Anticancer treatment has consisted of chemotherapy (Abraxane, Capecitabine), endocrine therapy (Letrozole), targeted therapy (Palbociclib, Olaparib), radiotherapy, and antiresorptive therapy (Denosumab)...Risk reducing bilateral salpingo-oophorectomy (plus hysterectomy) was performed in February 2021; histology identified an atrophic endometrium and no pathologic features.Gender affirming hormone therapy was commenced in October 2017 in the form of testosterone undecanoate 1000mg intramuscularly every 12 weeks...The impact of masculinising hormone therapy on the future risk of breast cancer remains unknown and further longitudinal data are required. Guidelines for pre- and post-operative breast screening after top surgery in high-risk transmasculine patients remain critically important.
- |||||||||| Prolia (denosumab) / Amgen
Comparative Effectiveness Of Antiresorptive Vs. Anabolic Therapy In Women With Type 2 Diabetes: Results From A Randomized Pilot Trial (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1585;
Till November 2023, 72-week follow up was completed for 23, 18, 16, and 14 participants in ZOL, DMAB, TPTD, and control groups, respectively. At 72 weeks, LS aBMD increased by 2.24% (95% CI: -0.03, 4.52) with ZOL, 0.19% (95% CI: -2.71, 3.10) with DMAB, 7.28% (95% CI: 3.11, 11.45) with TPTD and declined by -0.53% (95% CI: -3.47, 2.41) in controls (p=0.008).
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Use in a Patient With Osteogenesis Imperfecta Type 3 (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1582;
Data on patients with OI type 3 is scarce. Our patient continued to sustain fractures despite therapy with oral and intravenous bisphosphonates prompting us to use Romosozumab, off-label.
- |||||||||| Prolia (denosumab) / Amgen
Adult-Onset Hypophosphatasia Presenting as Low Alkaline Phosphatase Level Following Denosumab Use for Osteoporosis (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1579;
There is a need for better screening and diagnostic criteria for adult HPP patients whose ALP levels may not be initially low before initiating antiresorptive drugs for osteoporosis. The risk of adverse effects from therapy will likely vary significantly based on the clinical severity/presentation of HPP as some adults with lower ALP ranges might be more susceptible to developing atypical femur fractures (1).
- |||||||||| Prolia (denosumab) / Amgen
Adjuvant denosumab therapy for adult-onset central giant cell granuloma (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1578;
Denosumab exerts its therapeutic effect in giant cell lesions by inhibiting osteoclast maturation, thereby suppressing osteolysis and giant cell formation. Our case suggests it could be considered first line adjuvant treatment for patients with large CGCG lesions.
- |||||||||| Prolia (denosumab) / Amgen
PPI Breaks a Leg! An Unusual Case of Atypical Femur Fracture (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1566;
Overall, PPIs are positively associated with elevated fracture risk in multiple studies. Increased gastrin production and hypochlorhydria are the two main mechanisms that affect bone remodeling, decreasing bone turnover, impairing calcium absorption, and altering homocysteine levels through impairment of folate and vitamin B12 absorption.This case supports a potential association between long-term PPI use and atypical femur fractures.
- |||||||||| Prolia (denosumab) / Amgen, Decadron (dexamethasone) / Merck (MSD), Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Hypercalcemia of Immobilization (HCOM) Responding to COVID treatment: A mere coincidence or more? (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1558;
HCOM is managed by physical therapy, IV hydration, and IV bisphosphonates. Since hypercalcemia of immobilization is a sclerostin-mediated bone resorption process, a short course of steroids or the use of anti-sclerostin monoclonal antibody Romosozumab can be a reasonable treatment consideration however more research is needed for that.
- |||||||||| cinacalcet HCl / Generic mfg.
Management Strategies for Hypercalcemia in Breast Cancer with Bone Metastases: A Focus on Glucocorticoids and Cinacalcet (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1553;
This case demonstrates the unusual occurrence of elevated 1,25-dihydroxyvitamin D in the setting of solid tumor, thereby suggesting the utility of glucocorticoids as a treatment option for HCM resistant to usual therapy. It also shows the effectiveness of cinacalcet in managing non-PTH-mediated HCM, which possibly works via increased renal clearance of calcium and could be used as an additional effective therapeutic option in these patients.
|
